Elicio Therapeutics posts AMPLIFY-7P presentation on ELI-002 7P in metastatic mKRAS pancreatic cancer

Elicio Therapeutics, Inc

Elicio Therapeutics, Inc

ELTX

0.00
  • Elicio Therapeutics published an AMPLIFY-7P research presentation outlining a development path for ELI-002 7P in metastatic mKRAS pancreatic cancer.
  • Document highlights 3 confirmed complete radiographic and metabolic responses in metastatic PDAC patients who later received nivolumab-based therapy.
  • All three patients were MSS/MMR-proficient; two complete responses lasted at least 9 months, including one ongoing response.
  • Presentation frames the cases as hypothesis-generating, supporting prospective testing of ELI-002 7P with checkpoint inhibition in metastatic mKRAS PDAC.
  • Company outlines a staged Phase 1 strategy aimed at early efficacy signals within 3-6 months of study start.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.